Evogene Ltd. (TLV:EVGN)
244.80
+2.10 (0.87%)
Apr 24, 2026, 1:44 PM IDT
Evogene Market Cap
Evogene has a market cap or net worth of 29.63 million as of April 24, 2026. Its market cap has decreased by -11.62% in one year.
Market Cap
29.63M
Enterprise Value
33.77M
Revenue
12.28M
Ranking
n/a
PE Ratio
n/a
Stock Price
244.80
Market Cap Chart
Since October 15, 2007, Evogene's market cap has decreased from 113.15M to 29.63M, a decrease of -73.81%. That is a compound annual growth rate of -6.97%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 24, 2026 | 29.63M | 13.09% |
| Dec 31, 2025 | 26.20M | -44.67% |
| Dec 31, 2024 | 47.35M | -68.75% |
| Dec 31, 2023 | 151.55M | 64.52% |
| Dec 29, 2022 | 92.12M | -58.37% |
| Dec 30, 2021 | 221.26M | -59.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Bonus BioGroup | 485.94M |
| Geffen Residence & Renewal | 264.30M |
| Matricelf | 81.80M |
| Clal Biotechnology Industries | 50.98M |
| BioLineRx | 31.33M |
| BioLight Life Sciences | 24.18M |
| Can-Fite BioPharma | 19.65M |
| XTL Biopharmaceuticals | 18.92M |